Clinical Value Of Serum PSA And PSAD In Predicting Bone Metastasis Of Prostate Cancer

Objective: To investigate the clinical value of serum prostate specific antigen(PSA)and prostate specific antigen density(PSAD)in the prediction of bone metastasis of prostate cancer.Methods: Retrospective analysis of 63 cases of prostate cancer diagnosed by prostate biopsy in our hospital from January 2010 to October 2016,they all underwent radionuclide bone scan,According to the results of the e-xamination,it was divided into the bone metastasis group and the non-bone metastasis group of prostate cancer,the levels of PSA and PSAD in two groups were analyzed,and the relationship between PSA and PSAD and bone metastasis of prostate cancer was obtained.Results: There were significant differences in the levels of PSA and PSAD in the bone metastasis and non-bone metastasis of prostate cancer.With PSA>20ng/ml as diagnostic criteria to predict the bone metastasis of prostate cancer,the sensitivity was 89.7%,specificity was 76.5%,the serum PSAD>0.4 ng/(ml·cm3)to predict the bone metastasis of prostate cancer as diagnostic criteria,the sensitivity was 86.2%,specificity was 73.5%,the area under the ROC c-urve of the two were 0.919 and 0.866,Serum PSA>20ng/ml combined with PSAD>0.4 ng/(ml·cm3)as the standard to predict the clinical prostate cancer bone m-etastases,the sensitivity of diagnosis was 86.2%,the specificity was 85.3%.Conclusions: PSA and PSAD can be applied to the prediction of bone metastasis of prostate cancer,the combination of the two methods can improve the diagnostic value of bone metastasis of prostate cancer,the serum PSA>20ng/ml and PSAD>0.4ng/(ml·cm3)of the patients should be suspected in the presence of bone metastases,bone scan confirmed the diagnosis of positive.